-
1.
公开(公告)号:EP1999260A2
公开(公告)日:2008-12-10
申请号:EP07753837.9
申请日:2007-03-23
申请人: NOVARTIS AG , NOVARTIS-PHARMA GMBH
IPC分类号: C12N15/11 , A61K31/713 , C07H21/00 , A61P31/20
CPC分类号: C12N15/1137 , C12N15/111 , C12N15/1131 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/3515 , C12N2320/31 , C12N2310/3521
摘要: The invention relates to a double-stranded ribonucleic acid (dsRNA) for treating human papilloma virus (HPV) infection. The dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an HPV Target gene selected from among HPV E1, HPV E6 and the human E6AP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HPV infection and the expression of the E6AP gene using the pharmaceutical composition; and methods for inhibiting the expression of the HPV Target genes in a cell.
-
公开(公告)号:EP2171059A2
公开(公告)日:2010-04-07
申请号:EP08761002.8
申请日:2008-06-13
申请人: Novartis AG
发明人: VAN HEEKE, Gino , HICKMAN, Emma , DANAHAY, Henry Luke , TAN, Pamela , GEICK, Anke , VORNLOCHER, Hans-Peter
IPC分类号: C12N15/11 , A61K31/713
CPC分类号: C12N15/1138 , A61K31/713 , A61K45/06 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/351 , C12N2310/3513 , C12N2310/3515 , C12N2310/3521
摘要: The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides.
摘要翻译: 本发明涉及用于调节α-ENaC表达的组合物和方法,更具体地涉及通过化学修饰的寡核苷酸下调α-ENaC表达。
-
3.
公开(公告)号:EP2137313A2
公开(公告)日:2009-12-30
申请号:EP08718165.7
申请日:2008-03-25
IPC分类号: C12N15/11
CPC分类号: C12N15/1137 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/3515 , C12Y603/02019 , C12N2310/3521
摘要: The invention relates to a double-stranded ribonucleic acid (dsRNA) for treating human papilloma virus (HPV) infection. The dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of an HPV Target gene selected from the human E6AP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HPV infection and the expression of the E6AP gene using the pharmaceutical composition; and methods for inhibiting the expression of the HPV Target genes in a cell.
-
-